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Background: BRCA1 is a key protein in cell network, involved in DNA repair pathways and cell cycle. Recently, the
ENIGMA consortium has reported a high number of alternative splicing (AS) events at this locus in blood-derived
samples. However, BRCA1 splicing pattern in breast tissue samples is unknown. Here, we provide an accurate
description of BRCA1 splicing events distribution in breast tissue samples.
Methods: BRCA1 splicing events were scanned in 70 breast tumor samples, 4 breast samples from healthy
individuals and in 72 blood-derived samples by capillary electrophoresis (capillary EP). Molecular subtype was
identified in all tumor samples. Splicing events were considered predominant if their relative expression level was at
least the 10% of the full-length reference signal.
Results: 54 BRCA1 AS events were identified, 27 of them were annotated as predominant in at least one sample.
Δ5q, Δ13, Δ9, Δ5 and ▼1aA were significantly more frequently annotated as predominant in breast tumor samples
than in blood-derived samples. Predominant splicing events were, on average, more frequent in tumor samples than
in normal breast tissue samples (P = 0.010). Similarly, likely inactivating splicing events (PTC-NMDs, Non-Coding, Δ5
and Δ18) were more frequently annotated as predominant in tumor than in normal breast samples (P = 0.020),
whereas there were no significant differences for other splicing events (No-Fs) frequency distribution between
tumor and normal breast samples (P = 0.689).
Conclusions: Our results complement recent findings by the ENIGMA consortium, demonstrating that BRCA1 AS,
despite its tremendous complexity, is similar in breast and blood samples, with no evidences for tissue specific AS
events. Further on, we conclude that somatic inactivation of BRCA1 through spliciogenic mutations is, at best, a rare
mechanism in breast carcinogenesis, albeit our data detects an excess of likely inactivating AS events in breast
tumor samples.
Keywords: BRCA1, Splicing, Breast cancerBackground
Germ-line inactivating mutations in the breast cancer sus-
ceptibility gene BRCA1 (OMIM#113705) confer a marked
hereditary predisposition to breast and ovarian cancer
(HBOC). Yet, the role of BRCA1 as a driving gene in spor-
adic breast cancer is, at best, far from clear. Early studies
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[1]. Recent efforts aimed at elucidating the cancer
genome have confirmed this view. According to the
COSMIC database (http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/; last accessed 08/01/2015), BRCA1 somatic
mutations are very rare, regardless of the breast cancer
subtype analyzed (0.61% of breast cancer samples overall,
0.44% of basal-like breast cancers). While the analysis of
somatic mutations does not support a major role for
BRCA1 in sporadic breast carcinogenesis, other evidences
suggest that altered transcriptional regulation, rather thanl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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genesis [2-4]. For instance, it has been reported that
sporadic basal-like tumors frequently down regulate
BRCA1 expression [2]. As far as we know the role of
other possible BRCA1 inactivating mechanisms (such as
splicing alterations) in breast carcinogenesis has not
been comprehensively explored.
Recently, the ENIGMA consortium has analyzed nat-
urally occurring BRCA1 alternative splicing (AS) in
blood related RNA sources (commonly used for clinical
splicing assays) [5], identifying up to 63 AS events, and
supporting an AS model in which most non-mutually ex-
clusive AS events are randomly combined into individual
mRNAs molecules to produce probably hundreds of dif-
ferent RNA isoforms. To what extent these findings are
tissue specific is not known. The ENIGMA study sug-
gested that AS at the BRCA1 locus is similar in blood and
healthy breast tissue, albeit only one healthy breast tissue
was available (one breast epithelia sample from a cosmetic
surgery), thus limiting the power of the analysis [5].
In the present study, we have employed approaches
previously developed by the ENIGMA consortia [5] to
perform a comprehensive characterization of AS at the
BRCA1 locus in a cohort of 70 breast tumor samples
from patients diagnosed as having locally advanced
breast cancer, enrolled in a neoadjuvant clinical trial and
whose tumors have been classified into intrinsic sub-
types. For comparative purposes, we have characterized
as well AS in 72 blood samples from healthy control in-
dividuals and 4 healthy breast tissues (cosmetic surger-
ies). As far as we know, this is the most comprehensive
description of AS at the BRCA1 locus reported so far in
human breast cancer samples.
Methods
Study population
Tumor biopsy specimens were obtained from a set of 70
pre-treated patients, diagnosed as having locally advanced
breast cancer. These patients participated in a neoadjuvant
clinical trial (registered at the following Web site: http://
www.clinicaltrials.gov; identifier NCT00123929) in which
they were randomly assigned to receive four cycles of ei-
ther doxorubicin (75 mg/m2body surface area) or doce-
taxel (Taxotere, Sanofi-Aventis, Spain) (100 mg/m2body
surface area) every 3 weeks followed by surgery [6-9]. The
clinical trial was approved by the Hospital Clínico San
Carlos Ethics Committee, Madrid, Spain. Briefly, eligibility
criteria included the following: women aged between 18
and 78 years; clinical stage IIB, IIIA, or IIIB breast cancer;
and palpable breast tumors not amenable to breast-
preserving surgery. Before the start of the trial, an in-
formed consent was obtained from all participants.
Clinico-pathological features of the study population are
presented in Additional file 1: Table S1.Additionally, breast tissue samples were obtained from
four healthy individuals who underwent reduction mam-
moplasty. Similarly, whole blood was drawn from 72
healthy control donors (collected in EDTA tubes). All
patients signed an informed consent for voluntary dona-
tion of biological samples for research to the Hospital
Clínico San Carlos Biobank.
Laboratory analysis
Tumor biopsy specimens were obtained before neoadju-
vant chemotherapy. To check cellularity, an H&E image
was obtained from all tumors; only samples with more
than 80% tumor cells were used. Total RNA was ex-
tracted using the kit Qiagen RNeasy Mini Kit (Qiagen
Inc., Valencia, CA), following the instructions of the
manufacturer. Blood samples were kept ice-cold for a
maximum of 30 minutes before RNA extraction. Total
RNA was extracted from whole blood (200 μL) using a
MagnaPure Compact workstation and MagnaPure RNA
Isolation Kit according to the manufacturer’s protocol.
The amount of RNA was assessed using a Nanodrop ND-
1000 UV Spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE, USA). RNA integrity was assessed using
a kit (RNA 6000 Nano Chip kit), followed by analysis with
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).
Total RNA, 200 ng, was used as a template to obtain first-
strand cDNA using SuperScript First-Strand Synthesis
System for RT-PCR (Invitrogen, Parsley, UK), following
the manufacturer’s instructions.
Comprehensive characterization of AS events at the
BRCA1 locus was performed by semi-quantitative capil-
lary electrophoresis (capillary EP). The overall strategy
has been reported elsewhere [5]. For the purpose of this
study, we define AS events as those incorporating splice
junctions not present in the reference transcript Ensem-
ble ENST00000357654 (hereafter referred to as full-
length transcript). In brief, eight combinations of
forward and reverse primers located at exonic regions
(hereafter referred to as splicing assays) were used to
amplify cDNAs that later were analyzed by capillary EP.
Figure 1 shows representative examples of each of the
eight splicing assays. Primers sequences are shown in
Additional file 1: Table S2. All assays were performed in
a 25 ul reaction volume containing 1 ul of cDNA tem-
plate, 2.5 ul of 10× PCR reaction buffer with 20 mM
MgCl2 (Roche Diagnostics, Mannheim Germany), 0.2ul
of FastStart Taq DNA polymerase (Roche Diagnostics,
Mannheim Germany) 200 umol of each deoxynucleoside
triphosphate and 0.25 umol of each primer. Thermal
cycling consisted of an initial 10-minutes hold at 95°C,
followed by 30-second hold at 95°C, 30-second hold at
58°C, and 60-second hold at 72°C for 33 cycles. In all
cases, capillary EP analysis was performed in an ABI
3130 Genetic Analyzer (Applied Biosystems, Foster City,
Figure 1 (See legend on next page.)
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Figure 1 Representative examples of each of the eight cDNA splicing assays. Peak heights represent fluorescence intensity (scale on relative
fluorescent units (RFU)). GeneScan 500-LIZ standard peaks are colored in orange. Peaks imputed to AS events are colored in blue. Capillary EP
analysis permitted us to identify peaks imputed to transcripts carrying more than one independent splicing. For instance, assay 1–6 demonstrated
that Δ1Aq (6 bp shorter than the FL) is combined with most of the splicing events visualized in this amplicon. Similarly, a peak of 322 bp in
7-11B assay demonstrated the presence of transcripts containing Δ8p and Δ9,10. As shown in 7-11B assay Δ9,10 is 123 bp shorter than the FL. In
7–12 assay a peak of 361 bp can be imputed to the combination of Δ9,10+ Δ11q since this peak is 123 bp shorter than Δ11q peak.
Romero et al. BMC Cancer  (2015) 15:219 Page 4 of 8CA) using 50 cm capillary arrays filled with POP-7 and
GeneScan 500-LIZ (Applied Biosystems, Foster City, CA)
as internal size-standard. A standard electrophoresis
protocol was used in all cases (temperature 60°C, injection
15 sec at 1.6KVolts, and running 1800 sec at 15KVolts).
Peak heights under 100 RFU (Relative Fluorescent Units)
were not considered for analyses. Size-calling and peak
areas were analyzed with GeneMapper software version
4.0 (Applied Biosystems, Foster City, CA). Peak annota-
tion was performed as previously reported [5].
Relative quantification of individual AS events (expressed
as the average ratio between the peak area of that particular
event and the peak area of the full-length signal in the cor-
responding assay) allowed us to classify AS events as pre-
dominant (≥10% of the full-length signal) or minor (<10%).
AS events detected by the exons 7–12 assay were not clas-
sifiable because the full-length reference transcript contain-
ing exon 11 (>3300 bp) was not co-amplified. BRCA1
exons were named according to the Breast Core Inform-
ative (BIC) database nomenclature [10], so that the 22 cod-
ing exons of the reference full-length transcript are
numbered from 2 to 24 with no exon 4 defined. We have
designated splicing events as previously reported [5,11,12]
combining the following symbols: Δ (skipping), ▼ (reten-
tion), p (proximal), and q (distal). Structural and functional
annotation of AS events was performed as previously de-
scribed [5]. Briefly, functional annotation of BRCA1 AS
events includes: Non-Coding (splicing events eliminating
the full-length start codon), PTC-NMDs (splicing events
introducing Premature Termination Codons predicted to
induce the Nonsense-Mediated RNA Decay pathway),
No-FS (in-frame splicing events), FS-alternative STOP
(frame-shift events generating PTCs not predicted to in-
duce NMD as they are located in the most downstream
BRCA1 exons) and UTRs (splicing events modifying Un-
Translated Regions). Further on, based on functional an-
notation, we classify AS events into likely inactivating and
other AS events. The former category, referring to AS
events that render the corresponding transcript unable to
codify for functional BRCA1 proteins, includes Non-
Coding and PTC-NMD events, as well as two in-frame
splicing events that target the critical RING (Δ5) and
BRCT (Δ18) functional domains. By contrast, No-FS, FS-
alternative STOP, and UTR AS events, with no obvious
functional interpretation, were considered collectively as
other AS events.IHC FISH, Tumor grading and subtype assignation
Paraffin-embedded tumor samples from core biopsy
specimens were evaluated by immunohistochemical ana-
lysis for estrogen receptor (ER) (clone 1D5, 1:35; Dako
Cytomation, Glostrup, Denmark) and progesterone re-
ceptor (PR) (clone PgR 636, 1:50; Dako Cytomation).
After incubation with the primary antibodies, immunohis-
tochemical studies were performed using the Autostainer
link 48 (Dako Cytomation, Carpinteria, CA). The cut points
for ER and PR positivity were established at 1% or greater
of stained cells. Slides of all tumors were reviewed for diag-
nostic reassessment of the tumor histotype and histological
grade, in a blinded fashion. The amplification of ERBB2
was measured by FISH (fluorescence in situ hybridization).
The probes used were as follows: Centromere enumeration
probe 17, labeled in green; and locus-specific identifier
ERBB2 probe, labeled in orange (Vysis-Abbott, Downers
Grove, IL). Slides were prepared according to the manu-
facturer’s instructions. A positive result was defined as an
ERBB2 gene/chromosome 17 ratio of 2.2 or greater. A
minimum of 100 nuclei were counted per case.
Gene expression data from previously hybridized gene
expression microarrays [6,13] (available in the Gene Ex-
pression Omnibus repository database under accession
number GSE21997) was used for intrinsic subtype assign-
ment. Breast cancer molecular subtypes were identified
using the PAM50 and the Claudin-low (CLP) subtype pre-
dictors as previously described [14,15].
Statistical analysis
All analysis where restricted to the subgroup of predom-
inant splicing events (events representing >10% of the
full-length signal in at least one tumor sample) exclu-
sively. Association between two categorical variables was
assessed using the Χ2 or Fisher exact test in cases in
which more than 25% of the expected values were less
than five. P-values were corrected for multiple compari-
sons using False Discovery Rate (FDR) method [16]. For
quantitative variables, comparisons were assessed by T-
student test or Mann Whitney test when appropriate. P <
0.05 was considered for statistical significance. The statis-
tical analysis was performed using software R 3.0.1.
Results
Overall, we have identified in breast tissue samples most
of the BRCA1 AS events previously identified by the
Romero et al. BMC Cancer  (2015) 15:219 Page 5 of 8ENIGMA consortium in blood-derived samples (54 out of
63, see Additional file 1: Table S3) [5]. As previously ob-
served [5], most AS events were rather minor in most ana-
lyzed samples, with the notable exception that Δ1Aq, Δ8p,
Δ9,10, Δ14p and Δ5q (Table 1) were frequently identified
as predominant AS events, regardless of the tissue of origin.
Further on, the relative quantification of these AS events is
similar in breast tumor and blood samples, with Δ1Aq
expressed on average at similar levels than the full-length
reference and Δ8p, Δ9,10 and Δ14p, signals representing
roughly 35%. Nonetheless, Δ5q levels were higher in breast
tumor samples (P < 0.01) (Figure 2). Equally relevant, we
have not identified any breast specific AS event, neither in
healthy nor in malignant samples. Taken together, the dataTable 1 Predominant splicing events distribution by tissue
Variant name HGVS description Functional
annotation
Biotype
Δ8p c.442_444del3 No FS Splice ac
Δ14p c.4358_4360del3 No FS Splice ac
Δ1Aq c.-25_-20del6 UTR Splice do
Δ9,10 c.548_670del123 No FS multi-ca
Δ5q c.191_212del22 PTC-NMD Splice do
Δ13 c.4186_4357del172 PTC-NMD Cassette
Δ9 c.548_593del46 PTC-NMD Cassette
Δ5 c.135 _212del78 No FS Cassette
Δ2 c.-19_80del99 Non-Coding Cassette
▼1aA c.-20 + 1_-20 + 89ins89 UTR Splice do
Δ22 c.5333_5406del74 FS-alternative STOP Cassette
Δ2p c.-19_-7del13 UTR Splice ac
Δ10 c.594_670del77 PTC-NMD Cassette
▼4 c.135-4047_135-3932ins116 PTC-NMD Cassette
Δ8_10 c.442_670del229 PTC-NMD multi-ca
Δ3 c.81_134del54 PTC-NMD Cassette
Δ21 c.5278_5332del55 PTC-NMD Cassette
Δ15 c.4485_4675del190 PTC-NMD Cassette
Δ21_23 c.5278_5467de FS-alternative STOP multi-ca
Δ2,3 c.-19_134del153 Non-Coding multi-ca
▼13A c.4358-2785_4358-2729ins66 No FS Cassette
Δ21,22 c.5278_5406del129 No FS multi-ca
Δ8,9 c.442_593del152 PTC-NMD multi-ca
Δ17 c.4987_5074del88 PTC-NMD Cassette
Δ22,23 c.5333_5467del135 FS-alternative STOP multi-ca
Δ13p c.4186_4188del3 No FS Splice ac
Δ15_17 c.4485_5074del590 PTC-NMD multi-ca
P1 for significance of Fisher exact test for differences between observed and expect
healthy breast samples. P2 for significance of ×2 statistic or Fisher exact test, when
events frequency distribution in breast tumor samples and blood-derived samples.
predominant in blood- derived sample.suggests that, AS events at the BRCA1 locus in human
breast tissue and blood are similar, with no evidence for tis-
sue specific AS events. These observations support the clin-
ical use of blood samples as an adequate surrogate for
testing the spliciogenic effect of BRCA1 genetic variants.
Further on, our data suggests as well that somatic inactiva-
tion of BRCA1 through the acquisition of spliciogenic mu-
tations is, at best, an uncommon mechanism in breast
carcinogenesis.
While the above data indicates that, on average, AS at
the BRCA1 locus is similar in breast and blood samples,
Δ5q findings prompted us to explore the possibility that
more subtle splicing alterations targeting individual AS












ceptor shifts 1.000 1.000 NS 1.000 NS
ceptor shifts 1.000 1.000 NS 1.000 NS
nor shifts 1.000 1.000 NS 1.000 NS
ssette 0.971 1.000 NS 0.988 NS
nor shifts 0.857 0.750 NS 0.391 0.001
0.357 0.000 NS 0.000 0.049
0.203 0.000 NS 0.000 0.0175
0.200 0.250 NS 0.000 0.0001
0.200 0.250 NS 0.333 NS
nor shifts 0.157 0.000 NS 0.000 0.006
0.129 0.000 NS 0.031 NS
ceptor shifts 0.114 0.000 NS 0.059 NS
0.087 0.000 NS 0.000 0.07
0.086 0.000 NS 0.000 0.07
ssette 0.072 0.000 NS 0.000 0.082
0.071 0.000 NS 0.071 NS
0.071 0.000 NS 0.000 NS
0.071 0.000 NS 0.000 NS
ssette 0.071 0.000 NS 0.034 NS
ssette 0.043 0.000 NS 0.023 NS
0.043 0.000 NS 0.000 NS
ssette 0.043 0.000 NS 0.000 NS
ssette 0.014 0.000 NS 0.000 NS
0.014 0.000 NS 0.000 NS
ssette 0.014 0.000 NS 0.000 NS
ceptor shifts 0.014 0.000 NS 0.000 NS
ssette 0.014 0.000 NS 0.000 NS
ed values of AS events frequency distribution in breast tumor samples and
appropriate, for differences between observed and expected values of AS
Note that none of the 27 AS events listed is annotated more frequently as
Figure 2 Relative quantification of predominant splicing events. (A). The chart shows the ratios between peak areas of alternative splicing
events and peak areas of the reference full-length transcripts in tumor samples (T) and blood-derived samples (B). *(P < 0.01) (B). Representative
example of a cDNA splicing assays showing Δ1Aq, Δ8p, Δ9,10 and, Δ14p peak areas (blue). The assay allowed us to identify transcripts with different
combinations of splicing events such as Δ9, 10 +Δ8p. Interestingly, the assay predicts the existence of another splicing event involving ±16 bp
(X in the figure).
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were annotated as predominant (>10% of the reference
full-length signal) in at least one tumor sample (Table 1).
Focusing on individual AS events, we found that seven
(Δ5q, Δ13, Δ9, Δ5, ▼1aA, Δ10 and ▼4, all of them
likely inactivating) were more frequently annotated as
predominant in breast tumor samples than in blood-
derived samples, albeit in the case of Δ10 and ▼4 the
findings did not reach statistical significance (Table 1).
After FDR correction, the differences in Δ5q and Δ5 fre-
quency distribution between blood and tumor samples
remained significant (P = 0.014 and P = 0.003 respectively).
Similarly, we observed that, on average, the absolute
number of predominant splicing events per sample was
higher in tumor samples than in healthy breast tissue sam-
ples (6.8 vs. 5.0; P = 0.010). The same was true for peaks
corresponding to the combination of two or more splicing
events (8.9 vs. 5.7; P = 0.004). Additionally, we found that
likely inactivating AS events were, on average, morefrequently annotated as predominant in breast tumor
samples than in healthy breast samples (2.6 vs 1.0; P =
0.020), while the same effect was not true for other AS
events (4.1 vs 4.0; P = 0.689). Some representative exam-
ples of likely inactivating AS events occurring in breast
tumor samples are displayed in Additional file 1: Figure
S1. Overall, the data suggests an excess of likely inactivat-
ing AS events in breast cancer cells.
Finally, we explore the possibility that certain AS
events annotated as predominant in individual tumor
samples were associated with the intrinsic subtype, as
defined by PAM50 + CLP genomic profiling, but we did
not identify any obvious association.
Discussion
To our knowledge, this is the most comprehensive de-
scription of AS at the BRCA1 locus reported so far in
human breast samples. To perform this analysis, we took
advantage of recent studies conducted by the ENIGMA
Romero et al. BMC Cancer  (2015) 15:219 Page 7 of 8consortium for the characterization of naturally occurring
AS at the BRCA1 locus in blood related samples [5]. Ac-
cording to the ENIGMA consortium, pervasive AS at the
BRCA1 locus is observed in blood related samples, with
up to 63 individual AS events identified [5]. This observa-
tion was consistent with several genome-wide analyses
that have identify a strong association of high level AS loci
with intrinsically disordered protein/domains (IDPs/
IDDs), IDPs/IDDs with Hub proteins, and Hub proteins
with disease [17-19].
In the present study, we analyze to what extent this high
level of AS is observed also in breast related samples.
With this aim, we have characterized BRCA1 AS in 70
breast tumor samples and 4 healthy breast tissue samples.
For ethical reasons, it is difficult to access healthy human
breast samples, so that we have performed the study in a
very small cohort. Overall, our study concludes that AS at
the BRCA1 locus is similar in breast and blood samples.
First, most AS events previously identified in blood, 54
out of 63, have been identified as well in healthy and
tumor breast samples. Second, we have not identified any
novel AS event not previously described in blood. Third,
up to four AS events (Δ1Aq, Δ8p, Δ9,10, Δ14p) emerge as
predominant in almost all samples of both tissues. Four,
the relative semi-quantification of these predominant AS
events reveals similar profiles in both tissues, with Δ1Aq
representing roughly 90% of the reference full-length sig-
nal, Δ8p, Δ9,10, and Δ14p representing 30% (Figure 2). As
a corollary, we conclude that somatic inactivation of
BRCA1 through spliciogenic mutations is, at best, a rare
mechanism in breast carcinogenesis.
We have concluded that, on average, AS at the BRCA1
locus in breast and blood samples is very similar. Yet, in
the present study we addressed as well the possibility that
subtle quantitative alterations involving certain AS events
were detectable in individual breast tumor samples. Due
to the complexity of such analysis, in the present study we
have restricted ourselves to compare the average number
of predominant AS events detected in individual breast
and blood samples. Interestingly, our data supports an ex-
cess of predominant AS events in tumor samples, in par-
ticular AS events annotated as likely inactivating. Since
we have analyzed very few healthy breast samples, we can-
not rule out the possibility that this finding (and excess of
likely inactivating AS events in breast tumor samples) re-
flects tissue specific AS regulation, rather than a tumor
specific phenotype acquired in the carcinogenic process.
Further on, according to our data likely inactivating spli-
cing events are not associated with any particular breast
cancer subtype. Splicing deregulation represents a relevant
ethiopathogenic mechanism of some diseases, including
cancer [20]. Yet, further studies are needed to establish a
role, if any, for BRCA1 likely inactivating AS events in
sporadic breast carcinogenesis.A catalogue of AS events occurring at the BRCA1
locus in breast tissue sample is an essential requirement
for the design of adequate RNA splicing assays assessing
the pathogenicity of BRCA1 sequence variants. Indeed,
our findings of similar AS events in breast and blood
samples somehow validate the use of blood-derived sam-
ples for in vitro splicing assays testing the clinical rele-
vance of BRCA1 sequence variants, a key issue in
molecular diagnosis [12]. In addition, the results pre-
sented here will help researchers to analyze and validate
data from RNAseq experiments that are becoming in-
creasingly widespread. Moreover, tools for functional an-
notations of novel sequences (novel transcripts) and the
analyses of annotation data are clearly warranted. In this
way, our data might be useful for the development of
such tools.
Conclusions
Our results complement recent findings by the EN-
IGMA consortium, demonstrating that BRCA1 AS, des-
pite its tremendous complexity, is very similar in breast
and blood samples, with no evidences for tissue specific
AS events. Further on, we conclude that somatic inacti-
vation of BRCA1 through spliciogenic mutations is, at
best, a rare mechanism in breast carcinogenesis, albeit
our data detects an excess of likely inactivating AS
events in breast tumor samples.
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tumor samples.
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